tofacitinib + acitretin

This is a **combination therapy** consisting of **tofacitinib**, a Janus kinase (JAK) inhibitor, and **acitretin**, a second-generation oral retinoid. - **Tofacitinib** works by inhibiting several intracellular enzymes called Janus kinases (JAK1, JAK2, JAK3, and TYK2), blocking the JAK-STAT signaling pathway that leads to reduced pro-inflammatory cytokine activity and decreased immune response, particularly in autoimmune and inflammatory diseases[2][3][4]. - **Acitretin** is a synthetic analog of retinoic acid (a vitamin A derivative) that modulates epidermal growth and differentiation by binding to nuclear retinoic acid receptors (RAR and RXR families), primarily inhibiting abnormal keratinization and proliferation in the skin[6][8]. The combination has been used off-label in complex dermatological or autoimmune cases, e.g., in patients with rheumatoid arthritis or certain types of psoriasis, especially when monotherapies have failed or are inadequate. There are case reports and some clinical rationale for combining these agents, but there are no standardized or formal guidelines for this combination, and safety/efficacy data are limited[7].